Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/18/1/52/796884/mdl355.pdf
Reference20 articles.
1. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005;Goldhirsch;Ann Oncol,2005
2. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2003
3. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel;Smith;J Clin Oncol,2002
4. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival;Heys;Breast Cancer Res Treat,2005
5. Adjuvant docetaxel for node-positive breast cancer;Martin;N Engl J Med,2005
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nanoparticle Albumin-Bound-Paclitaxel Instead of Standard Paclitaxel in Adjuvant Chemotherapy Regimen for Breast Cancer Under COVID-19 Pandemic—A Single Center Feasibility Study in China;Science of Advanced Materials;2022-02-01
2. Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34;British Journal of Cancer;2021-03-24
3. Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer;World Journal of Oncology;2020
4. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer;Cochrane Database of Systematic Reviews;2019-02-18
5. Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells through the Upregulation of the RhoA/MLC Pathway;Journal of Breast Cancer;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3